FDA: Eylea Approval Expanded to Include Diabetic Retinopathy

Share this content:
FDA: Eylea Approval Expanded to Include Diabetic Retinopathy
FDA: Eylea Approval Expanded to Include Diabetic Retinopathy

WEDNESDAY, March 25, 2015 (HealthDay News) -- U.S. Food and Drug Administration approval of Eylea (aflibercept) has been expanded to treat diabetic retinopathy among people with diabetic macular edema, the agency said Wednesday in a news release.

The injected drug Eylea is intended to be used in tandem with appropriate therapies to control blood glucose, blood pressure, and cholesterol, the FDA said.

The drug's safety and effectiveness were evaluated in clinical studies involving 679 people. The most common side effects included bleeding of the conjunctiva, eye pain, cataracts, floaters, and increased intraocular pressure.

Eylea was first approved in 2012 to treat wet age-related macular degeneration, and also was sanctioned to treat diabetic macular edema and macular edema secondary to retinal vein occlusions.

The drug is marketed by Regeneron Pharmaceuticals, based in Tarrytown, N.Y.

More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Bayer Stops U.S. Sale of Essure Birth Control Implant

Bayer Stops U.S. Sale of Essure Birth Control ...

Problems with device include chronic pain and perforations of the uterus and fallopian tubes

C.S. Mott Poll Addresses Child Safety at Amusement Parks

C.S. Mott Poll Addresses Child Safety at Amusement ...

2016 saw U.S. emergency departments deal with 30,000 injuries linked to amusement parks, carnivals

Greening Vacant Land Improves Neighborhood Mental Health

Greening Vacant Land Improves Neighborhood Mental Health

Cleaning up vacant lots in resource-limited urban settings can aid residents' mental health

is free, fast, and customized just for you!




Already a member?

Sign In Now »